Pyxis Oncology, Inc. (PYXS) Income Statement
PYXS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPYXS revenue and net income
Where PYXS's revenue goes
2025Each bar shows an amount and its share of revenue. PYXS kept −574.5% of revenue as net income.
PYXS profit margins
PYXS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −14.2% | — | — | — |
| Gross profit | −26.8% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PYXS quarterly EPS vs estimates
Pyxis Oncology beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 2, 2026 (estimate $-0.27).
PYXS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $2.4M | $475,000 | $2.0M | $1.8M | $1.3M | $444,000 | — |
| Gross profit | $11.5M | $15.7M | −$2.0M | −$1.8M | −$1.3M | −$444,000 | — |
| Research & development | $73.7M | $58.7M | $49.6M | $86.1M | $51.1M | $8.6M | $1.2M |
| Sales, general & admin | $22.2M | $25.4M | $32.6M | $37.4M | $18.7M | $3.8M | $1.7M |
| Total operating expenses | $95.9M | $105.1M | $82.2M | $123.5M | $69.7M | $12.4M | $2.9M |
| Operating income | −$84.4M | −$89.5M | −$82.2M | −$123.5M | −$69.7M | −$12.9M | −$2.9M |
| Interest income | $3.6M | $7.0M | $6.9M | $2.8M | $23,000 | $66,000 | $107,000 |
| Interest expense | — | — | — | $2.8M | $6.3M | $0 | $0 |
| Income before taxes | −$78.2M | −$79.5M | −$73.8M | −$120.7M | −$76.0M | −$12.8M | −$2.8M |
| Income taxes | $1.4M | −$2.2M | $1.8M | −$2.8M | $5.6M | −$66,000 | −$107,000 |
| Net income | −$79.6M | −$77.3M | −$73.8M | −$118.0M | −$76.0M | −$12.8M | −$2.7M |
| EBITDA | −$73.7M | −$65.5M | −$71.9M | −$122.8M | −$75.3M | −$12.4M | −$2.8M |
| EPS (diluted) | −$1.29 | −$2.02 | −$1.85 | −$3.65 | −$19.38 | −$18.67 | −$2.74 |
| Gross margin | 82.8% | 97.1% | — | — | — | — | — |
| Operating margin | −609.2% | −554.1% | — | — | — | — | — |
| Net margin | −574.5% | −478.9% | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.0M | $0 | $2.8M | $0 | $3.4M | $0 | $0 | $16.1M | $3.4M | $0 |
| Cost of revenue | — | $459,000 | −$432,000 | $0 | $535,000 | $552,000 | $1.7M | $731,000 | $585,000 | $475,000 | $763,000 | $677,000 |
| Gross profit | — | −$459,000 | $11.5M | $0 | $2.8M | −$552,000 | $1.7M | −$731,000 | −$585,000 | $15.7M | $2.7M | −$677,000 |
| Research & development | $16.1M | $19.6M | $21.7M | $17.8M | $17.1M | $17.0M | $14.0M | $17.7M | $14.0M | $13.0M | $11.6M | $14.7M |
| Sales, general & admin | $9.9M | $4.4M | $5.2M | $5.7M | $5.4M | $5.9M | $5.1M | $6.0M | $6.1M | $8.2M | $6.2M | $10.7M |
| Total operating expenses | $26.0M | $23.9M | $29.8M | $23.5M | $22.6M | $22.9M | $40.1M | $23.8M | $20.0M | $21.3M | $17.8M | $25.4M |
| Operating income | −$26.0M | −$24.4M | −$18.3M | −$23.5M | −$19.8M | −$22.9M | −$40.1M | −$23.8M | −$20.0M | −$5.6M | −$17.8M | −$25.4M |
| Interest income | $255,000 | $457,000 | $600,000 | $774,000 | $995,000 | $1.2M | $1.6M | $1.8M | $2.0M | $1.6M | $1.6M | $1.7M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $1.7M | — |
| Income before taxes | −$25.3M | −$23.3M | −$17.0M | −$22.0M | −$18.1M | −$21.2M | −$37.7M | −$21.2M | −$17.3M | −$3.3M | −$15.6M | −$23.0M |
| Income taxes | — | — | $1.1M | — | $283,000 | — | −$2.2M | — | — | $1.1M | $3.9M | −$523,000 |
| Net income | −$25.3M | −$23.3M | −$18.1M | −$22.0M | −$18.4M | −$21.2M | −$35.6M | −$21.2M | −$17.3M | −$3.3M | −$15.6M | −$23.0M |
| EBITDA | −$25.0M | −$22.8M | −$14.1M | −$21.5M | −$17.5M | −$20.6M | −$18.6M | −$20.5M | −$16.7M | −$2.1M | −$14.9M | −$22.5M |
| EPS (diluted) | −$0.40 | −$0.37 | −$0.29 | −$0.35 | −$0.30 | −$0.35 | −$1.32 | −$0.35 | −$0.29 | −$0.06 | −$0.33 | −$0.56 |
| Gross margin | — | — | 103.9% | — | 100.0% | — | 50.0% | — | — | 97.1% | 77.7% | — |
| Operating margin | — | — | −165.7% | — | −700.4% | — | −1,177.8% | — | — | −34.7% | −519.5% | — |
| Net margin | — | — | −164.0% | — | −650.9% | — | −1,045.6% | — | — | −20.2% | −456.1% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PYXS's financial statements (latest annual report filed March 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PYXS financial results
In fiscal year 2025 (ended December 31, 2025), Pyxis Oncology reported revenue of $13.9 million, down 14.2% from the year before. It had a net loss of $79.6 million, a net profit margin of −574.5%. Diluted earnings per share came to −$1.29.
See the PYXS stock overview for the latest quote and news, or the PYXS chart for price history and technical indicators.
PYXS income statement FAQ
What is Pyxis Oncology's annual revenue?
Pyxis Oncology reported total revenue of $13.9 million for fiscal year 2025, which ended on December 31, 2025. That was down 14.2% from $16.1 million the previous year.
Is Pyxis Oncology profitable?
No. Pyxis Oncology reported a net loss of $79.6 million in fiscal 2025, a net profit margin of −574.5%; its operating margin was −609.2%.
What is Pyxis Oncology's gross margin?
Pyxis Oncology's gross margin was 82.8% in fiscal 2025: for every $100 of revenue, Pyxis Oncology kept $83 after the direct cost of its products and services.
How much does Pyxis Oncology spend on research and development?
Pyxis Oncology spent $73.7 million on research and development in fiscal 2025, 531.8% of revenue.
What are Pyxis Oncology's earnings per share?
Pyxis Oncology earned $-1.29 per diluted share in fiscal 2025, compared with $-2.02 a year earlier.
When will Pyxis Oncology report its next earnings?
Pyxis Oncology is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens.
When does Pyxis Oncology's fiscal year end?
Pyxis Oncology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 23, 2026.